| Literature DB >> 29027968 |
Rui Liu1,2,3, Lei Zhou4, Yan Zhang5, Nai-Juan Sheng6,7, Zhi-Kang Wang8,9, Ti-Zhi Wu10,11, Xin-Zhi Wang12,13, Hao Wu14,15.
Abstract
Dipeptidyl peptidase-IV (DPP-IV) inhibitory peptides were rapidly identified from Ruditapes philippinarum hydrolysate. The hydrolysate was fractionated by ethanol precipitation and preparative reverse phase high-performance liquid chromatography (RP-HPLC). The fraction which showed the highest DPP-IV inhibitory activity was then analyzed by a high-throughput nano-liquid chromatography electrospray ionization tandem mass spectrometry (nano-LC ESI-MS/MS) method, and the sequences of peptides were identified based on the MS/MS spectra against the Mollusca protein data from the UniProt database. In total, 50 peptides were identified. Furthermore, molecular docking was used to identify potential DPP-IV inhibitors from the identified peptides. Docking results suggested that four peptides: FAGDDAPR, LAPSTM, FAGDDAPRA, and FLMESH, could bind pockets of DPP-IV through hydrogen bonds, π-π bonds, and charge interactions. The four peptides were chemically synthesized and tested for DPP-IV inhibitory activity. The results showed that they possessed DPP-IV inhibitory activity with IC50 values of 168.72 μM, 140.82 μM, 393.30 μM, and >500 μM, respectively. These results indicate that R. philippinarum-derived peptides may have potential as functional food ingredients for the prevention of diabetes.Entities:
Keywords: Ruditapes philippinarum; bioactive peptide; dipeptidyl peptidase-IV; identification; molecular docking; nano-LC-MS/MS
Mesh:
Substances:
Year: 2017 PMID: 29027968 PMCID: PMC6151561 DOI: 10.3390/molecules22101714
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1(A) DPP-IV inhibitory activities of RPHs produced by different proteases. The IC50 of RPHs produced by Papain is 672.12 μg/mL; (B) DPP-IV inhibitory activities of 60% precipitate and supernatant, and the IC50 of 60% supernatant is 733.93 μg/mL.
Figure 2(A) RP-HPLC profile of the supernatant of papain-produced RPH; (B) DPP-IV inhibitory activities of subfractions from 60% supernatant of RPHs separated by RP-HPLC; M2 showed DPP-IV inhibitory activity of 487.42 μg/mL.
Figure 3(A) Sequence of actin and the distribution of identified peptides. (B) Identification of peptide FAGDDAPR (F22–R29).
Figure 4GRAVY index value (A) and Mw distribution (B) of the identified peptides based on the total number of peptides.
Figure 5The binding model of peptide inhibitors to DPP-IV in docking studies. Best docking position of peptides FAGDDAPR (A); LAPSTM (B); FAGDDAPRA (C); and FLMESH (D) at the DPP-IV pocket. Red circles represent the amino acid residues belong to Pocket S1, and blue circles represent the amino acid residues belong to Pocket S2.
Figure 6DPP-IV inhibitory activity of the four peptides: (A) FAGDDAPR; (B) LAPSTM; (C) FAGDDAPRA; and (D) FLMESH.
Figure 7Lineweaver—Burk double-reciprocal plot for DPP-IV activity in the absence and presence of four peptides at different inhibitory concentrations. (A) Diprotin A (0, 10, and 20 μM) as reference; (B) peptide FAGDDAPR (0, 150, and 300 μM); (C) peptide LAPSTM (0, 150, and 300 μM); (D) peptide FAGDDAPRA (0, 250, and 500 μM); and (E) peptide FLMESH (0, 400, and 800 μM).